Abstract 3977
Background
The study aims at investigating the use of anti-oxidant L-carnosine for prevention of acute oxaliplatin neurotoxicity in colorectal cancer pts and to observe L-carnosine effect on Tumor necrosis factor alpha (TNF α) as a neuro-inflammatory cytokine.
Methods
This is a pilot study that recruited 60 pts using prospective randomized controlled design. Eligible Pts (non-diabetic) were randomly assigned to two arms. Arm A (30 pts) received FOLFOX-6 regimen (oxaliplatin, 5FU & leucovorin) and Arm B (30 pts) received FOLFOX-6 regimen and oral L-carnosine 1000 mg daily all along the treatment. All recruited pts were followed for three months, then both arms were analyzed for neuropathy incidence/grade and any additional toxicities according to NCI-CTC version 4. Pre-treatment and after 3 months TNF α serum levels were collected and tested.
Results
No neuropathy were detected in 35.3% of pts in Arm B compared to only 3.3% in Arm A. Also 50 % of pts in Arm B developed grade I neuropathy compared to 36.7% in Arm A and only 2.9% of Arm B pts developed grade II neuropathy compared to 60 % of arm A pts. Regarding TNF α serum levels, Arm B and Arm A at base line had comparable mean serum levels (0.04ng/ml & 0.03ng/ml) however the percentage reduction of Arm B serum level was higher than Arm A (0.02ng/ml & 0.001ng/ml, respectively p value = 0.0001). No toxicities were observed due to L-carnosine addition.
Arm A and Arm B regarding the neuropathy grade and TNF before/after 3 months of treatment
| Arm A (Control group) N = 30 | Arm B (Test group) N = 30 | P-value | |
|---|---|---|---|
| Neuropathy grade 0 1 2 Drop out | 1 (3.3%) 11 (36.7%) 18 (60.0%) 0 (0.0%) | 12 (35.3%) 17 (50.0%) 1 (2.9%) 4 (11.8%) | 0.0002 |
| TNF before start of treatment (ng/ml) Mean ± SD Range | 0.03 ± 0.01 0.021 – 0.06 | 0.04 ± 0.01 0.02 – 0.06 | 0.664 |
| TNF after 3 months of treatment (ng/ml) Mean ± SD Range | 0.03 ± 0.01 0.016 – 0.044 | 0.02 ± 0.01 0.01 – 0.04 | 0.0001 |
Conclusions
L-carnosine reduced the incidence of acute oxaliplatin induced neuropathy, delayed the onset of chronic neuropathy and decreased TNF α serum levels without additional toxicities. Further studies are warranted to examine the full potential of L-carnosine in chemotherapy induced neuropathy.
Clinical trial identification
Local registry: CairoUniv 387658
Legal entity responsible for the study
Faculty of Medicine, Ain Shams University
Funding
Faculty of Medicine, Ain shams university Misr international university
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract